Day 2 :
Keynote Forum
Ramakrishna Pidaparti
Wipro Technologies, USA
Keynote: Evolving towards using real world data and reall world evidence for regulatory decisions
Time : 10:00-10:40
Biography:
Abstract:
TBA
Keynote Forum
Dilip Ghosh
Nutriconnect, Australia
Keynote: Phytopharmaceuticals: An emerging platform in modern medicine
Time : 10:00-10:40
Biography:
Abstract:
A comprehensive review to be presented which shows the plant kingdom as an almost inexhaustible reservoir of potential drugs. The longstanding, successful use of herbal drug combinations in traditional medicine makes it necessary to find a rationale for the pharmacological and therapeutic superiority of many of them in comparison to isolated single constituents. As a result a new category, “Phytopharmaceutical” has emerged in several countries. There are many definitions but the core essence is “Phytopharmaceutical drug includes purified and standardised fraction with defined minimum four bio-active or phytochemical compounds (qualitatively and quantitatively assessed) of an extract of a medicinal plant or its part, for internal or external use of human beings or animals for diagnosis, treatment, mitigation or prevention of any disease or disorder but does not include administration by parental route” (CDSCO, Govt of India, 2016). In last decade we have seen the sluggish growth of Herbal/ Ayurvedic products and decrease in Pharma R&D output in terms of reduction in number of NCEs and increasing cost of new drug discovery. Current allopathic practice is unable to meet the unmet needs of multicomponent drug for multi target diseases. A number of problems, such as usefulness of RCTs in herbal medicine which are connected with the search for new prototype drugs of biological origin is also described. Special attention will be given on role of natural products in therapy; as biologically active compounds as such, as starting materials for (semi)synthetic drugs and, also as source of inspiration or as models for the synthesis of new drugs with better therapeutic, chemical or physical properties than the original compounds.
Keynote Forum
Sadish Kumar Shanmugam
ITS College of Pharmacy, India
Keynote: Bioactive compounds from Gelidiella acerosa, a red alga
Time : 10:40-11:20
Biography:
Presently, Dr. S. Sadish Kumar is the Director of I.T.S College of Pharmacy, Ghaziabad, India. He has been working as a Professor since 2010. He has over 2 decades of Research and Teaching experience.
He is a member of various professional bodies including Royal Society of Chemistry (RSC), UK. He has published 2 books, 30 research articles & presented research papers at conferences held in South Korea, USA, Germany & Egypt and guided over 30 MPharm research projects in Marine and other natural products, guiding PhD projects as well.
His biography has been cited in Marquis Who’s Who in Medicine & Healthcare. He has been selected and commemorated for International Einstein Award for Scientific achievement, International Health Professional of the year to mention a few. His research thirst on Marine algae is widely noted.
Abstract:
Algal resources have a tremendous potential to be explored for the benefits of the mankind. Gelidiella acerosa is a genus of Red algae (Family: Gelidiellaceae) with high economic value found in many parts of India. As Gelidiella acerosa is used in the production of high quality agar, reported to possess a variety of phytoconstituents including Flavonoids, Alkaloids, Tannins, Proteins, Sulfated polysaccharides, Sulfono glycolipid, Sesquiterpenes, Monoterpenes, Phenols and various pharmacological activities, prompted us to investigate on this red alga with its hexane, ethyl acetate and methanolic extracts.
Among the extracts, methanolic extract of Gelidiella acerosa exhibited the highest percentage of free radical scavenging activity (68.42%) by Invitro DPPH assay which was comparable to that of the standard Ascorbic acid (76.55%). Methanolic extract also possessed the highest anti-inflammatory potential followed by ethyl acetate and hexane extracts in the Carrageenan induced paw edema and Cotton pellet induced granuloma models and it was found to be significant at p<0.001. The percentage inhibition was found to be 64.60% when compared to the standard, Diclofenac sodium (70.45%) at 10mg/kg concentration.
The antioxidant and anti-inflammatory activity of methanolic extract could be attributed to the highest amount of Flavonoid and Phenolic content, which were estimated to be 48.5 mg/g Quercetin and 34.34 mg/g Gallic acid equivalent respectively. Further investigations should be carried out to discover other potential phytoconstituents and pharmacological activities of G. acerosa.
- Pharmaceutical Analysis | Nanomedicine and Nanotechnology | Drug Safety and Pharmacovigilance | Industrial and Physical Pharmacy
Location: Mercure Melbourne Albert Park
Session Introduction
Martha Rowe
Rowe’s Speech and Swallowing, Australia
Title: Effects of papaya enzymes on the viscocity of saliva and oral hygiene in patients with a dry mouth
Time : 12:20-12:50
Biography:
Martha Rowe, Speech Pathologist since 2000 has spent years researching and developing papaya enzyme formulation as a result of her own difficulties with a dry mouth following surgery due to facial trauma in 2008. She has worked in both Public and Private hospitals across Victoria and has been involved in clinical studies and patients management in the areas of dysphagia and dry mouth.
Abstract:
A dry mouth syndrome occurs when there is not enough saliva (spit) in the mouth. A dry mouth is a symptom of an underlying problem, rather than a disease in itself. Causes may include drugs or medication, dehydration, mouth breathing, Sjogren's syndrome, infection, nerve problems and some cancer treatments. Our research aims were Investigate effects of papaya enzymes in patients with dry mouth, Create a product that super cedes current products on the market, Determine microbiological and immunological outcomes and Investigate Quality of Life Measures. Our results found categorically that papya enzymes assist with maintaining a clean and moistened mouth, free of bacteria and assisted with the increase in saliva flow.
Venkateshwarlu K
Vaagdevi College of Pharmacy, India
Title: Studies on pharmacokinetic interactions and toxicity of metformin with glimepiride
Time : 13:50-14:20
Biography:
Venkateshwarlu K has completed his PhD from Kakatiya University, Warangal, India and he is working as Professor and Head, Department of Pharmaceutical Analysis, Vaagdevi college of Pharmacy. He has published more than 20 papers in reputed various associations like APTI etc.
Abstract:
The combination of Metformin and Glimepiride is widely used to treat type 2 diabetes. The present study was carried out to study the pharmacokinetic interactions between these two drugs used in combination. An available RP-HPLC method for simultaneous estimation of Metformin and Glimepiride was revalidated for future use. Albino rats of either sex were randomly distributed into four groups of six animals in each; they are housed in well ventilated Aluminium cages and maintained on uniform diet and temperature with 12hr light and dark cycle. In this study, the blood was collected from orbital sinuses using heparinised capillaries into a micro centrifugation tubes contain anti coagulant at 0, 1, 2, 4, 6, 8, 12 hrs after treatment. Plasma was separated by centrifugation and stored at -20ºC until further analysis. These samples are used to analyze for pharmacokinetic and pharmacodynamic toxicological i.e. SGOT-SGPT, Complete Blood Picture (CBP) and serum Creatinine Clearance. Metformin and Glimepiride levels were estimated by a sensitive RP-HPLC method. This study proves, single and multiple doses Metformin increases plasma concentrations of Glimepiride. There is significant increase in the AUC and decrease in clearance. In single dose studies this change could be because of the transient induction in CYP2C9. When Glimepiride is given in repeated doses (15 days) there could be induction of the microsomal liver CYP2C9 subsequently increasing the metabolism, decreasing clearance of Metformin & increasing the overall AUC. This combination has clearly shown the beneficial effect on the CBP i.e. significant improvement in blood cell count, lymphocytes and neutrophills in particular.
Angela Drew
Camargo Pharmaceutical Services, USA
Title: Drug approval pathways in the US: A focus on the 505(b)(2) pathway and the role of BA/BE studies
Time : 14:20-14:50
Biography:
Angela Drew is a Product Ideation Consultant at Camargo Pharmaceutical Services. Angela has an academic background in inflammatory diseases and cancer, and a regulatory background in FDA submissions for approval via the 505(b)(2) regulatory pathway. Angela has industry experience with US and Australian regulatory submissions, and experience with global clinical program oversight. She is experienced in Product Ideation and design of drug development programs.
Abstract:
Background: There are 3 major pathways through which drugs can be approved in the US, depending on their similarity to existing drugs, and the source of data that will support the application (see image). The 505(b)(2) regulatory pathway relies to some extent on existing data that comes from sources other than Sponsor studies, and results in smaller development programs than that of previously unknown drugs. A 505(b)(2) approval usually relies heavily on well-designed bioavailability/ bioequivalence studies to bridge to the existing data.
Methodology & Theoretical Orientation: This talk will cover the basics of the US regulatory pathways, with special emphasis on products intended for approval via the 505(b)(2) pathway. Which products are appropriate for this pathway, typical features of 505(b)(2) development programs, and when a biowaiver is appropriate will be discussed. Further, a review of products that gained approval based on studies reported in the literature is provided.
Conclusions & Significance: The 505(b)(2) regulatory pathway allows a Sponsor to rely on existing data and therefore reduce the size or scope of the development program. BA/BE studies are often the tenet of a 505(b)(2) approval, and have distinct goals compared with pharmacokinetic studies conducted for 505(b)(1) or generic products. It is therefore critical that BA/BE studies be designed with the nuances of the 505(b)(2) pathway in mind, and to collect additional data that will further reduce the number of studies required for approval. When BA/BE studies are well designed and conducted, and with FDA feedback and input at the appropriate times, a Sponsor can expect reduced cost and time to market.
Ashraf H Abadi
German University in Cairo, Egypt
Title: Discovery of highly potent anti-HCV with new core scaffolds and new conformational aspects
Time : 14:50-15:20
Biography:
Ashraf Abadi has completed his PhD from the College of Pharmacy, University of Florida, USA and Cairo University. He is the head of Pharmaceutical Chemsitry Department, Faculty of Pharmacy and Biotechnology, German University in Cairo and former Dean of the Faculty. He has published more than 80 papers in reputed journals and 7 patents and has been serving as an editorial board member and reviewer of reputed international pharmaceutical sciences journals. He supervised more than 6- Master and Ph.D. theses in the field of Drug Discovery and Pharmaceutical Chemistry.
Abstract:
NS5A is a dimeric protein and an interesting target to inhibit the replication of HCV. Reported here are two series of symmetric molecules with the scaffolds of 4, 4'-(buta-1,3-diyne- 1,4-diyl) dianiline core- and 3, 3'-(buta-1,3-diyne- 1,4-diyl) dianiline core, connected to a L/D-proline moiety, and capped with the methyl, ethyl, butyl, isobutyl and benzyl carbamate of L/D-valine, L/D-leucine and L-isoleucine amino acids. The compounds showed inhibitory effect on the replication of HCV genotype 1b in vitro with EC50s in the low picomolar range and SI50s of several orders of magnitude, Also some of the compounds showed pan-genotypic activitiy. Higher activities were associated with compounds showing curving of the core scaffolds that leads to better fit and interaction with the desired target.
C S Kandasamy
RVS College of Pharmaceutical Sciences, India
Title: Design, fabrication and clinical evaluation of HEP-PRO - an indigenous polyherbal extract as a potent hepatoprotective
Time : 15:20-15:50
Biography:
C.S. Kandasamy has completed his PhD at the age of 42 years from SunRise University and postgraduate studies from the TamilNadu Dr. M.G.R. Medical University, Chennai. He is the Professor & Vice Principal of RVS College of Pharmaceutical Sciences, a premier Pharmaceutical educational service organization. He has published more than 25 papers in reputed journals and has been serving as an editorial board member of repute.
Abstract:
Background: Diseases are destroyers of health, well being, and life. So, Arogya is the main constituent for excelling in life. Jaundice is one disease which has manifested itself as a curse for many years. Even today, there is no good allopathic medicine for treatment and complete cure of jaundice. This study aims to make a formulation for the cure of jaundice by combining various herbals to cure jaundice.
Methods: Based on the ethnomedical literature reviews, the crude drugs such as cardamom, ajowan, cinnamon, coriander, cumin, clove, ginger, and nutmeg were collected and subjected to various pharmacognostical, phytochemical, and analytical studies to assess its quality. After confirming the quality, the hepatoprotective polyherbal formulation (HEP-PRO) was formulated and their efficacy was analysed using various analytical and pharmacological studies. To assess the safety of HEP-PRO, clinical trials were conducted using this formulation at Ayushkaram Ayurveda Hospital, Coimbatore after obtaining Human Ethical Clearance approval by IEC, Institute of Applied Dermatology, Kasaragod.
Results: The present study has been carried out in 30 patients. All the patients were given HEP-PRO at a dose of 60 ml three times a day one hour after food. HEP-PRO provided significant relief in pyrexia by 36% (P<0.015), fatigue and yellow discoloration of sclera by 27 & 39% respectively (P<0.025), and yellow discoloration of urine by 32% (P<0.010). This also has reduced the yellow discoloration of nail and yellow discoloration of skin by 60% with a P value of 0.001, which is also statistically significant.
Conclusion: HEP-PRO has proved its efficacy in the management of jaundice.
Ahmed M A Masaad
Taif University, KSA
Title: New discovery of treatment of complicated hemorrhoids without surgery
Biography:
Ahmed M A Masaad is concerned with discovery of new drugs and he have innovations in many new drugs and drug delivery systems. He have memberships of many scientific society and editor of PSC journal. He published more than twenty scientific researches in many sides of pharmacy, he have discovered new treatment of cancer of colon and skin. He possess innovative certificates in drugs delivery system and new drugs which published in scientific journal.
Abstract:
Hemorrhoids, also called piles, are vascular structures in the anal canal. In their normal state, they are cushions that help with stool control. They become a disease when swollen or inflamed; the unqualifiedly term "hemorrhoid" is often used to refer to the disease. The signs and symptoms of hemorrhoids depend on the type present. Internal hemorrhoids are usually present with painless, bright red rectal bleeding when defecating. External hemorrhoids often result in pain and swelling in the area of the anus. If bleeding occurs it is usually darker. The new treatment is mainly depend on mechanism of contract the connective tissue surrounding the venous around anus by effervescent tannin base with strong anti-bacterial, antifungal and anti-viral effect of formula. The safety of drugs was tested in rabbits, rats first and then the experiment was done in hundreds of patient under license of ethics committee of Taif University. The percentage of cure conducted was 99%, this success leads to relive of pain over millions of patients around the world and minimize the risk of surgery treatment and cost beside quick relive of disease in two to three weeks with no chance of relapse of disease again.
Prakash Kinthada
Sri Vidyanikethan Engineering College, India
Title: Transition metal complexes/organometallic compounds as anticancer/anti HIV drugs or in pharmaceutical industry
Biography:
Prakash Kinthada is a Professor in Chemistry at Sri Vidyanikethan Engineering college, JNTU University in Ananthapur, A. Rangam Peta, Tirupathi, India.
Abstract:
Cancer is a dreadful disease and any practical solution in combating this disease is of paramount importance to public health. Cancer patients have burdened by drug induced toxic side effects, and no turned to seek help from the complementary and alternative medicine hoping for a better cure. Research on Platinum based drugs and Non Platinum based drugs is a Multi-Million Dollar Industry in USA and there is every need to produce safe drugs for the cure of this monstrous disease. Flavonoids have a long history of use in traditional medicines in many cultures. The phytochemical, curcumin is one of the major dietary flavonoid, belonging to a group of flavonol, Curcumin is a natural polyphenol. It is highly potential molecule capable of preventing and treating various cancers. Various dietary chemo preventive agents, turmeric powder or its extract are broadly used as therapeutic preparations in Indian System of medicine. We provide a summarized synthesis and structural determination of Curcumin Oxime, Curcumin Thiosemicarbazone derivative of Gold (III) complex. The use of these analogs for prevention of cancer tumor progression and treatments of human malignancies. A pharmacologic agent for treating and/or preventing cancer, among other diseases and conditions, and particularly breast, prostate, and pancreatic cancer, in humans and animals. The novel pharmacologic agent is an isoflavonoid or isoflavonoid mimetic covalently attached to a cytotoxic pharmacophore that, preferably has the ability to conjugate with a metal salt to form a more potent metal complex, particularly a Au (III) complex and other complexes of Platinum, Palladium, Ruthenium, Copper etc.
My talk would mainly encompass different Transition Metal Complexes/Organometallic Compounds that are presently used as drugs, especially Anticancer and Anti-HIV drugs, apart from Anti-inflammatory, Antimicrobial, Antibacterial and diseases like Arthritis and Parkinson’s Disease etc. The talk would mainly focus on the use of Medicinal Chemistry and it’s application to Drug Design and Development in Pharmaceutical Industry , especially Transition Metal Complexes and Organometallic Compounds viz. Gold, Platinum, Palladium And Ruthenium apart from Copper, Cobalt, Iron, Nickel, Zinc, Cadmium etc.
The main emphasis of my talk would be on Different class of Ligands, their Schiff’s Bases and Transition Metal Complexes especially Au, Pt, Pd and Ru, with the main aim of designing, developing very novel small molecules, as possible and extremely potential candidates as Anti-cancer and Anti-HIV drugs. The talk would provide an overview of current programs being undertaken in our laboratories, especially focused on the development of potent ligands capable of recognizing Binding sites and diverse strategies employed by my group for elucidation of Anti-Cancer and Anti-HIV drug Leads to Circumvent the problem caused by Cis-Platin.
We have synthesized and characterized several phytochemicals from Traditional Medicinal Plants and isolated some phytochemicals and made the corresponding Oximes, Thiosemicarbazones and Substituted thiosemicarbazones as ligands and synthesized, characterized, structurally elucidated their Transition Metal Complexes especially with Gold, Platinum, Palladium, Ruthenium, Copper etc. and Studied their Anticancer Activity, Nuclease activity etc. and tested their potential as Anticancer Drugs.
The main aim of our extensive/preclinical Pharmaceutical development program is to investigate the use of these extremely novel small molecules-metal complexes/compounds of phytochemicals, flavanoids etc., which have very interesting structural features and properties and hence are excellent candidates as Anti-Cancer and Anti-HIV drugs .The main aim of our research is Design ,Development and Synthesis of Transition Metal Complexes/ Organometallic Compounds that would certainly help to bring this force of nature from BENCH to BEDSIDE and enhance Cancer Killing with less toxic effects and would certainly lead to initiation of clinical trials.
Ezharul H Chowdhury
MONASH University, Malaysia
Title: The impact of nanotherapeutics in transforming the medicine
Biography:
Ezharul H Chowdhury is currently holding an Associate Professor position and a cluster leader of 'Biomedical Engineering' under Advanced Engineering Platform (AEP) at MONASH University (Sunway Campus). Prior to this appointment, he was a Senior Lecturer at International Medical University (IMU) since September 2008 and an independent Assistant Professor of Tokyo Institute of Technology (Tokyo Tech) as well as a Visiting Professor at Shizuoka Cancer Center Institute since 2006. He was awarded with 'Doctor of Engineering' in 2003 by Tokyo Tech where he also carried out a post-doctoral study and subsequently, served as a team leader. He has pioneered the development of a range of pH-sensitive inorganic nanoparticles as smart tools for efficient and targeted intracellular delivery of genetic materials, gene-silencing elements, proteins and classical anti-cancer drugs. He is currently applying this smart nanotechnology for the treatment of cancer, particularly breast carcinoma and cardiovascular diseases, such as diabetes. His team is now conducting pre-clinical trials with some interesting nano-formulations of classical anti-cancer drugs, therapeutic gene(s) and anti-sense RNAs (siRNAs). His research team is thus one of the leading groups in the world, having original and unique contributions in this multidisciplinary field. Currently he is supervising 8 PhD students and 1 Master student. His research projects have so far been funded internally through institutional grants as well as externally by the Japanese Government's Ministry of Education, Culture, Sports, Science & Technology (MEXT), Japan Society for the Promotion of Science (JSPS), the Malaysian Ministry of Science, Technology and Innovation (MOSTI) and Ministry of Higher Education (MOHE). He works as editorial board members for 5 international journals. His outstanding contributions have so far produced over 70 publications in the international journals of high repute and 5 Japanese and US patents.
Abstract:
Regardless of the administration routes, delivery of small molecule drugs to their target sites of action historically poses one of the biggest challenges due to their homogeneous tissue distribution, renal clearance and lack of target specificity. Nanotherapeutics have evolved as novel drug formulations at dimensions of roughly 1–100 nanometers by virtue of the integration of nanotechnology with medicine for treating and preventing critical human diseases effectively and precisely. The favorable pharmacokinetics with prolonged circulation time, selective endothelial permeability at several target tissues and high specificity for biological targets are the attractive attributes of nanopharmaceuticals driving the pharmaceutical industries to conduct a large number of pre- clinical and clinical trials, with enormous successes seen in the past in getting approval and commercialization of nanotechnology-based medical products. Diversified approaches based on synthetic, recombinant, hybridoma and phage display technologies have been undertaken to fabricate a variety of nanoparticulate and macromolecular carriers and drugs in order to overcome the multi-step extracellular and intracellular barriers and to facilitate development of novel strategies for therapeutic delivery and imaging.
Biography:
Dawit Simegnew has completed his BPharm at the age of 24 years from University of Gondar. Currently, he is working as Clinical pharmacist at Shambu General Hospital. He has 4 published original research articles in peer-reviewed journals. He was also awarded by Ethiopian pharmaceutical association in 2014/15 for his outstanding academic achievements in pharmacy.
Abstract:
The sale of antibiotics without medical prescription has been observed in many countries. The practice is more pronounced in developing and low income countries where legislations and regulations are weak. In these countries, antibiotics are illegally purchased without medical prescriptions and very little effort has been made to tackle the situation. The role of pharmacists in contributing to healthcare remains debatable. In Ethiopia, there are deficiencies in the quality of current professional practice. Community pharmacists are now seen as retailers and businessmen rather than health care providers. Ethiopians are therefore left to accept the helpful and harmful practices such pharmacists. Self-medication with antibiotics is a universal problem and variations regarding such practices are obvious around the globe. The practice cuts across culture, gender, age, health status, social status, race and occupation. Irrational use of antibiotics increases the risk of bacterial resistance and adverse drug reactions. It has been found to produce various adverse effects in humans. It is the objective of this paper to discuss the irrational use and non-prescription sale of antibiotics in Ethiopia. It will discuss the evidence, the concept of self-medication, resistance and interactions, legislation, probable solutions, changes
in practice and the concept of sustainability which would help guarantee the appropriate sale and rational use of antibiotics in Ethiopia.
Muluye Melak Zenebe
Taiwan International Graduate program (TIGP), Taiwan
Title: Isolation, Structural Elucidation, and Bioactivity Studies of leaf extract of Vernonia amygdalina
Biography:
Muluye Melak Zenebe has completed his MSc at the age of 25 years from University of Gondar and now he is a PhD candidate at Taiwan international graduate program (TIGP), Taipei, Taiwan. He has published two papers in reputed journals.
Abstract:
Vernonia amygdalina (VA) is a tropical African plant of the Asteraceae family and is occasionally cultivated for its medicinal uses, which include as a treatment for diarrhea, skin wounds, fever mastitis and warms infection. The aim of this study is to isolate and elucidate the structure of some of the chemical constituents from the leaf of Vernonia amygdalina and its bioactivities. Methanol extract of Vernonia amygdalina, after repeated chromatography led to the isolation of a different compound, one of this compound (MM-4) is partially characterized based on the spectral data (IR, 1H NMR, 13C NMR, and DEPT) and Extracts from Vernonia amygdalina have been shown to have antimicrobial activity.
Zaka Un Nisa
Quaid-i-Azam University, Pakistan
Title: Injection and sharp waste disposal practices at community clinics
Biography:
Zaka Un Nisa is working as a Faculty of Medicine in Quaid-i-Azam University in Islamabad, Pakistan.
Abstract:
Health care waste disposal is an alarming issue in these days. Improper disposal of injections and sharp wastes at open places exposes people to the risk of transmission of infectious diseases. Inappropriate methods of managing, treatment and disposal of health care waste can lead to an adverse effect on public health. This study highlights the unsafe disposal of injection and sharp waste in Rawalpindi, Pakistan. This study is conducted to explore the injection and sharp waste disposal practices at the community level clinics. In-depth scientific analysis study including the interviews of sanitary workers working in different community clinics is conducted. 65% claimed that they disposed of waste (syringes, swabs, dressings, needles) which they collected from clinics at open places and 35% stated that they dispose of waste in municipal bins. None of them has ever got training regarding injections and sharp waste disposal. Only 25% sanitary workers were aware of the hazardous effect of unsafe disposal of injection and sharp waste. 75% stated that they get injured one or more time while disposing of syringes. The reasons they stated of having injury were lack of time, lack of awareness regarding the transmission of infectious disease. There is an urgent need to develop safe and sustainable waste disposal method that is feasible at the clinic level. It is found that injections and sharp wastes from clinics are handled and disposed of together with domestic waste. It is also concluded that the duty of health care waste disposal is delegated to illiterate people who perform their duties without adequate knowledge and protective measures. Therefore, it is recommended that government and local health authorties should give immediate attention to this issue and setup a proper sustainable clinic waste disposal system.
- Pharmacognosy and Phytochemistry | Pharmacy Education and Practice
Location: Mercure Melbourne Albert Park
Session Introduction
Godfrey Habil Mudhune
Western Sydney University, Australia
Title: Hormone replacement therapy (HRT) in menopause: exploring the relationship between breast cancer risk factors and patterns of use amongst women in Queensland
Time : 11:40-12:10
Biography:
Godfrey Habil Mudhune is an epidemiologist, pharmacist and certified pharmacovigilance professional. He completed his Doctor of Pharmacy (PharmD) from the University of Nairobi and postgraduate studies at James Lind Institute, Singapore and the Western Sydney University, Australia.
He is a researcher at the Western Sydney University’s Translational Health Research Institute and an independent research consultant in several projects. His research interests are in cancer epidemiology and pharmacoepidemiology.
Abstract:
Background: The use of menopausal hormone replacement therapy in Australia declined by 55% from 2001 to 2005 following the publication of the Women’s Health Inititive trial findings, which highlighted an increased risk of breast cancer (Velentzis et al., 2016). In 2010, an estimated 539 cancers in Australia were attributable to menopausal hormone therapy, 453 breast (3.4%), 67 endometrial (3.1%) and 19 ovarian cancers (1.6%) (Jordan et al., 2015). It was further estimated that if 25% less women used hormone therapy 141 cancers would be prevented and the sole use of estrogen only products would prevent 240 cancers.
Aim: To explore the relationship between the use of menopausal hormone therapy and pre-exiting non-modifiable breast cancer risk factors; personal or family history, early menarche or low parity. It was based on analysis of questionnaire data collected by the BreastScreen Queensland programme.
Results: A positive personal history of breast cancer did not significantly influence the use of HRT, OR 1.117 (95% CI, 0.8945 – 1.3930), p=0.3274. However, women with a positive family history of breast cancer were less likely to have used any HRT compared to those with no family history, OR 0.8528 (95% CI, 0.7635 – 0.9526), p=0.00478. No significant difference in HRT use was noted between mothers and non-mothers, OR 1.101 (95% CI, 0.9702-1.2490), p=0.1360.
Conclusion: Of the examined non-modifiable breast cancer risk factors, only a family history influenced the use of HRT. The pre-existence of non-modifiable breast cancer risk factors has a minimal effect on the pattern of HRT use amongst women in Queensland.
Saraswathi Sompaga
Osmania University, Australia
Title: Organic extracts of Pelargonium graveolens L´Her and in silico docking studies
Time : 12:10-12:40
Biography:
Saraswathi Sompaga is a Ph.D. research scholar in Biotechnology and Genetics from Osmania University. She has completed her M.Sc. in Biotechnology and B.Sc. Gold Medalist from Osmania University. Her research work is mainly focused on Phytochemistry, Biotechnology, Oncology and Bioinformatics. She has published 4 research papers in peer review national and International journals and she has worked as Assistant Professor for graduates and under graduate students.
Abstract:
Pelargonium graveolens is a well-known medicinal plant for essential oil and has therapeutic value in the treatment of diarrhea, dysentery, fever, respiratory tract infections, liver complaints, wounds, gastroenteritis, hemorrhage and bladder disorders. The objective of this study is to evaluate organic extracts of P. graveolens and its anti-cancer activity and docking studies. P. graveolens dry powder was extracted in different organic solvents through two conventional methods Maceration and Soxhlet to show the efficient method for non-volatile compounds and organic extracts purity characterized based on elution peaks of HPLC and FTIR spectrometric analysis. Among organic extracts, ethyl acetate and methanol showed significant values in Total phenolic content, anti-oxidant, anti-bacterial and anti-cancer activity. HeLa cell lines were cultured under sterile conditions and treated with varied concentrations of organic extracts and they showed the most significant IC50 values in methanol (149.4+0.3) and ethyl acetate (146.4±0.2) of soxhlet extract were as (114.9± 0.5) and (131.9 ±0.3) of maceration extract. GC-MS analysis ethyl acetate extract (Soxhlet) identified 25 non-volatile compounds and 1HNMR peaks eluated in between δ 0.67 0 to δ 8.134 were indicating the presence of aromatic rings structures. Bioinformatics molecular virtual docking study showed the potential non-volatile compounds interactions with HPV E6 protein. The study concludes P. graveolens organic extracts shows the anti-cancer activity and does poses active non-volatile compounds.
Biography:
Ronnell John R Gonzales is from Philippines.
Abstract:
Natural colorants are used in the coloration of food, handicraft items, toys, textiles and in leather processing. Many of the color-yielding plants are used as medicines in various traditional medicinal systems. Interest for natural colorants has increased dramatically worldwide due to the awareness of possible toxicity that can be caused by modern synthetic dyes. Synthetic colors have been banned in certain countries due to allergic and carcinogenic symptoms that they can cause. More eco-friendly colorants are now being developed to replace synthetic dyes which can be toxic and hazardous to health. Thus, the researchers wanted to study natural colorants from three botanical sources namely, Areca carechu, Bixa orellana and Hibiscus rosa-sinensis as possible alternative for the commercially used Food, Drug and Cosmetic colorant, Allura Red. UV-Vis Spectrometry was used to measure the transmittance of the samples which were used to obtain their CIELAB values and to compare the colorants quantitatively. Natural colorant from Areca catechu, Bixa orellana, and Hibiscus rosa-sinensis mean L* values were 21.6097, 44.3664 and 19.0708 respectively; mean a* values were 89.2146, 65.3665 and 69.7741 respectively; and mean b* values were 99.0016, 110.3789 and 21.6674 respectively. These results revealed that the natural colorants from Areca catechu, Bixa orellana, and Hibiscus rosa-sinensis all fall within the dark, red and yellow spectra of colors. Using One Way Analysis of Variance (ANOVA), it was found out that both the natural colorants from A. catechu and B. orellana yielded p-values of 0.042 and 0.024 respectively. These are both lower than the level of significance at µ 0.05 which means that there is a significant difference between the combined CIELAB values for color characterization of the natural colorants obtained from A. catechu and B. orellana to that of Allura Red. Thus it can be inferred that they can’t be utilized and further studied as possible alternative colorants to Allura Red. Only H. rosa-sinensis yielded a p-value of 0.641 that is greater than the level of significance at µ 0.05. This means that there is no significant difference between the combined CIELAB values for color characterization of the natural colorant obtained from Hibiscus rosa-sinensis to that of the standard, Allura Red making it a potential alternative. It can also be inferred through such data that among the three natural colorants that were analyzed in this study, the natural colorant from H. rosa-sinensis is the closest to Allura Red in term of combined color characteristics.
Donghua Cao
University of Chinese Academy of Sciences, China
Title: Trichiliasinenoids A-C, three novel 6,7-secomexicanolide limonoids with a 7,29-linkage from Trichilia sinensis
Biography:
Cao Donghua is a PhD candidate from Xishuangbanna Tropical Botanical Garden, Chinese Academy of Sciences and University of Chinese Academy of Sciences. Her Research Interest lies at the crossroads of chemistry and biology, and endeavors to discover novel active natural products from medicinal plant. She has published 3 papers in reputed journals
Abstract:
Meliaceous limonoids, characteristic chemical markers of the Meliaceae family, are natural products with both fascinating structures and potential bioactivities that have attracted interest from both natural products chemists and synthetic chemists in the past half century. As part of a continuing search for structurally interesting and biologically important limonoids from the Meliaceae family, the leaves and twigs of Trichilia sinensis collected from Xishuangbanna, Yunnan province of China were investigated. Trichilia sinensis Bentv, a shrub, is native to the south of China and Vietnam, and it has traditional applications for the treatment of several diseases such as abdominal pain caused by Ascaris lumbricoides, chronic osteomyelitis, scabies, and eczema in folk medicine. The three novel rearranged mexicanolide-type limonoids (Trichiliasinenoids A-C) with an unprecedented C-29-C-7 connecting carbon skeleton formed by migration of C-7 from C-6 to C-29 of a mexicanolide-type limonoid precursor were isolated from the leaves and twigs of Trichilia sinensis. Their structures were assigned by spectroscopic analysis, and the absolute conï¬gurations were determined by X-ray crystallography and CD calculation. A possible biosynthetic pathway of Trichiliasinenoids A was also proposed. The three new limonoids were evaluated for their cytotoxic activity against human myeloid leukaemia (HL-60), hepatocellular carcinoma (SMMC-7721), lung cancer (A-549), breast cancer (MCF-7), and colon cancer (SW480) cell lines by MTS assay. Trichiliasinenoid B showed cytotoxicity against HL-60 cells, SMMC-7721 with an IC50 value of 5.2 mM and 30.6 mM, respectively, whereas other limonoids were inactive and comparable to the cisplatin positive control (IC50: 1.1–17.3 m M).
Ji Hyun Park
Ewha Womans University College of Pharmacy, South Korea
Title: Incidence and risk factors associated with venous thromboembolism in spine surgery using national representative patient sample in Korea
Biography:
Ji Hyun Park is working in Ewha Womans University College of Pharmacy at Seoul in South Korea.
Abstract:
Objective: This study aimed to identify the incidence of risk factors and the utilization of thromboprophylaxis for perioperative venous thromboembolism (VTE) in patients undergoing spine surgery using National Health Insurance claims data in Korea.
Methods: The incidence of VTE in adult patients with spine surgery was extracted from 2014 National Inpatient Sample dataset provided by the Health Insurance Review & Assessment Service (HIRA-NIS-2014), a sample of all patients using medical services in Korea. The association of patient and surgery procedure variables, including VTE prophylaxis were determined with multivariable logistic regression
Results: In 2014, total incidence of VTE was found to be 1.5% (314) among 20,900 spine surgeries in Korea. Multivariable logistic regression analysis identified several independent predictors of VTE, including age over 80, length of stay (over 10 days), vein diseases, cancer, prolonged surgery (over 2 hours), perioperative blood transfusion (over 2 liters), cardiovascular diseases, and respiratory diseases. Only 5.7% of total spine surgeries is provided with VTE prophylaxis.
Conclusion: Patients undergoing spine surgery in Korea represent a population at a higher risk for VTE, however, relatively less concerned by care providers. Understanding the risk factors associated with perioperative VTE in spine surgery may provide an opportunity for early intervention and risk stratification in this population.
Biography:
Anteneh Assefa Kebede has completed his MSc in Pharmaceutics from Addis Ababa University, the premium university in the country, and B.Pharm from University of Gondar, College of Medical Sciences. He is now serving as a lecturer in the department of Pharmacy, college of Medical and Health Sciences, Wachemo University, which is a government University. Currently he is serving as the dean of the school of Pharmacy. The two names mentioned above are my supervising professors during the research work.
Abstract:
Starch is the most commonly used pharmaceutical disintegrant in tablet formulations. The aim of the present study was to assess the disintegrant property of Ethiopian potato (Plectranthus edulis) starch in comparison to Irish potato starch and its optimization in paracetamol tablets formulations - prepared by wet granulation method. Tablet properties such as crushing strength, friability, disintegration time, and dissolution rate of the tablets were studied for both comparison and optimization studies. The results of comparative study showed that the properties of paracetamol tablets formulated with both starches as disintegrants were affected by their concentration and the compression force (CF); and P. edulis starch exhibited a favorably comparable disintegrant property with Irish potato starch in paracetamol tablet formulations. The study also showed that the CF and disintegrant concentration had significantly affected the response variables (i.e., the crushing strength, friability and disintegration time); hence, these factors were further optimized using central composite statistical design. The optimal conditions were obtained at a CF of 14.40 KN and disintegrant concentration of 5.96%. Under these conditions, the crushing strength, friability and disintegration time were 101.8 KN, 0.3% and 1.34 min, respectively. These values closely matched with the predicted values of the responses at the aforementioned levels of the factors. Thus, the results of this study indicated that Ethiopian potato (P. edulis) can be used as an alternative source of starch for its application as a disintegrant in the tablet formulations.